APRI - Apricus Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.301
-0.013 (-4.26%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.314
Open0.310
Bid0.000 x 1800
Ask0.000 x 1000
Day's Range0.290 - 0.310
52 Week Range0.250 - 3.340
Volume596,837
Avg. Volume859,933
Market Cap8.478M
Beta (3Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press15 days ago

    Apricus: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 12 cents. In the final minutes of trading on Wednesday, the company's shares hit 35 cents. A year ago, they were trading at $1.67. ...

  • Associated Press3 months ago

    Apricus: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 10 cents. In the final minutes of trading on Thursday, the company's shares hit 27 cents. A year ago, they were trading at $1.33. ...

  • What Does Apricus Biosciences Inc’s (NASDAQ:APRI) Share Price Indicate?
    Simply Wall St.5 months ago

    What Does Apricus Biosciences Inc’s (NASDAQ:APRI) Share Price Indicate?

    Apricus Biosciences Inc (NASDAQ:APRI), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM over the last few months, increasingRead More...

  • With A -24.18% Earnings Drop, Is Apricus Biosciences Inc’s (NASDAQ:APRI) A Concern?
    Simply Wall St.6 months ago

    With A -24.18% Earnings Drop, Is Apricus Biosciences Inc’s (NASDAQ:APRI) A Concern?

    After looking at Apricus Biosciences Inc’s (NASDAQ:APRI) latest earnings update (31 March 2018), I found it helpful to revisit the company’s performance in the past couple of years and compareRead More...

  • Associated Press6 months ago

    Apricus: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 14 cents. In the final minutes of trading on Thursday, the company's shares hit 26 cents. A year ago, they were trading at $1.16. ...

  • Benzinga7 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) stock was trading higher ...

  • Reuters7 months ago

    Apricus mulls options; to sell U.S. rights to Vitaros

    Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug Administration asked it to make a new formula for the product. Shares of the company fell 24 percent to 32 cents in premarket trading, valuing the company at $7.5 million.

  • Reuters7 months ago

    FDA asks for new formulation of Apricus' erectile dysfunction cream

    Drugmaker Apricus Biosciences Inc said on Monday the U.S. regulator directed it to develop a new formulation for its erectile dysfunction cream, Vitaros, which was rejected in February. The U.S. Food And ...

  • Market Exclusive8 months ago

    Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why

    Edge Therapeutics, Inc. (NASDAQ:EDGE) is grabbing all of the headlines in the biotechnology space heading into the close of this week on news that a trial rooted in one of its lead development assets has failed to hit the mark. The trial in question was looking at a drug called EG-1962. This is one of […] The post Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why appeared first on Market Exclusive.

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of APRI earnings conference call or presentation 1-Mar-18 9:30pm GMT

    Q4 2017 Apricus Biosciences Inc Earnings Call

  • Associated Press9 months ago

    Apricus reports 4Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 16 cents. In the final minutes of trading on Thursday, the company's shares hit 87 cents. A year ago, they were trading at $2.88. ...

  • At $0.9401, Is Apricus Biosciences Inc (NASDAQ:APRI) A Buy?
    Simply Wall St.9 months ago

    At $0.9401, Is Apricus Biosciences Inc (NASDAQ:APRI) A Buy?

    Apricus Biosciences Inc (NASDAQ:APRI), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...

  • Benzinga9 months ago

    Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

    The FDA decided favorably on four of the six major PDUFA decisions due in February , with Valeant Pharmaceuticals Intl Inc (NYSE: VRX )'s Salix Pharma unit and its partner Norgine announcing an extension ...

  • Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session
    Zacks9 months ago

    Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session

    Shares of Apricus Biosciences (APRI) rose about 9% yesterday.

  • Market Exclusive9 months ago

    Here’s What’s Moving Apricus Biosciences And Pacira Pharmaceuticals

    Apricus Biosciences, Inc. (NASDAQ:APRI) is an early mover in the biotechnology space this week, with the company putting out an update on a regulatory development from its lead development asset. Unfortunately, for both the company and its shareholders, the update lands squarely on the negative end of the spectrum. So what happened? Apricus just reported […] The post Here’s What’s Moving Apricus Biosciences And Pacira Pharmaceuticals appeared first on Market Exclusive.

  • Benzinga9 months ago

    What's Next For Apricus Biosciences' Vitaros?

    Apricus Biosciences Inc (NASDAQ: APRI ) receded 67.4 percent Friday and continued down Tuesday after the U.S. Food and Drug Administration issued a response letter for Vitaros. The FDA declined to approve ...

  • Interested In Apricus Biosciences Inc (NASDAQ:APRI)? Here’s What Its Recent Performance Looks Like
    Simply Wall St.9 months ago

    Interested In Apricus Biosciences Inc (NASDAQ:APRI)? Here’s What Its Recent Performance Looks Like

    In this commentary, I will examine Apricus Biosciences Inc’s (NASDAQ:APRI) latest earnings update (30 September 2017) and compare these figures against its performance over the past couple of years, asRead More...

  • Is It “Game Over” After Apricus Biosciences Inc (APRI) FDA Rejection?
    SmarterAnalyst9 months ago

    Is It “Game Over” After Apricus Biosciences Inc (APRI) FDA Rejection?

    Apricus Biosciences Inc (NASDAQ:APRI) shares are collapsing today, down nearly 65%, following the news that the FDA has issued the company a complete response letter, rather than a green light to begin marketing its topical erectile dysfunction (ED) drug Vitaros. The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form, identifying deficiencies related to Chemistry, Manufacturing and Control (CMC) and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation. Apricus CEO Richard W. Pascoe commented, "We are disappointed with the outcome of the review given the substantial amount of CMC, clinical and non-clinical data and analysis provided to the FDA in the Vitaros resubmission.

  • Reuters9 months ago

    Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

    The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell. The drugmaker was hoping to sell Vitaros, possibly through commercial partner Allergan Plc, to patients unable to use oral medications and also looking for less invasive existing options.

  • Benzinga9 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! The Coca-Cola Co (NYSE: KO ) stock was trading higher ...

  • Reuters9 months ago

    U.S. FDA declines to approve Apricus' erectile dysfunction cream

    Apricus Biosciences Inc said on Friday the U.S. Food and Drug Administration declined to approve Vitaros, a cream-based treatment for erectile dysfunction, in its present form. The FDA flagged certain ...

  • Should You Buy Apricus Biosciences Inc (APRI) Now?
    Simply Wall St.last year

    Should You Buy Apricus Biosciences Inc (APRI) Now?

    Apricus Biosciences Inc (NASDAQ:APRI), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highs ofRead More...